Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Information source: Samsung Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Depression; Antidepressant Drug Adverse Reaction
Intervention: SSRI treated group (Drug); non-SSRI treated group (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Samsung Medical Center Official(s) and/or principal investigator(s): Doh Kwan Kim, M.D.,Ph.D., Principal Investigator, Affiliation: Samsung Medical Center
Overall contact: Doh Kwan Kim, M.D.,Ph.D, Phone: 82-2-3410-0946, Email: jungshil.back@sbri.co.kr
Summary
The Purpose of this study is to predict antidepressant response in advance using
pharmacogenomics and peripheral biological markers in depressed patients.
Clinical Details
Official title: Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: all pharmacogenetic and biological marker variables cause drug response
Secondary outcome: all clinical cause drug response
Detailed description:
The difficulties to treat depressed patients are 1)the patients don't respond to
antidepressant is about 40% of which, and 2) The time lag is existed until the patients
respond to antidepressant and show the treatment effects.
If it is predicted the response of antidepressant in advance, it would be overcome such
problems. Drug response generally is known to be related to the individual genetic
information and the environmental factors. We are going to investigation about
antidepressant response using these approaches.
Eligibility
Minimum age: 25 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. 25 < age <85
2. major depressed patients satisfied with the diagnosis criteria depression of DSM-IV
3. interview with one more patient's family member for objective diagnosis and final
diagnosis decision by agreements of two more psychiatric physicians
Exclusion Criteria:
1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4
weeks
2. potential study participants for pregnancy, significant medical conditions, abnormal
laboratory baseline values, unstable psychiatric features(eg. suicidal), history of
alcohol of drug dependence, seizures, head trauma with loss of consciousness,
neurological illness, or concomitant Axis I psychiatric disorder.
Locations and Contacts
Doh Kwan Kim, M.D.,Ph.D, Phone: 82-2-3410-0946, Email: jungshil.back@sbri.co.kr
Samsung Medical Center, Kangnam, Seoul 135-710, Korea, Republic of; Recruiting DohKwan Kim Doh Kwan Kim, ph.D, M.D., Principal Investigator
Additional Information
Starting date: April 2006
Last updated: June 4, 2015
|